Efficiency of CYP2C9 Genetic Test Representation for Automated Pharmacogenetic Decision Support

被引:12
|
作者
Deshmukh, V. G. [1 ]
Hoffman, M. A. [2 ]
Arnoldi, C. [2 ]
Bray, B. E. [1 ]
Mitchell, J. A. [1 ]
机构
[1] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT 84112 USA
[2] Cerner Corp, Kansas City, MO USA
关键词
Pharmacogenetics; clinical decision support systems; SNP; allele; CYTOCHROME-P450; CYP2C9; DOSE REQUIREMENT; WARFARIN; METABOLISM; GENOMICS; ANTICOAGULATION; THERAPY;
D O I
10.3414/ME0570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives: We investigated the suitability of representing discrete genetic test results in the electronic health record (EHR) as individual single nucleotide polymorphisms (SNPs) and as alleles, using the CYP2C9 gene and its polymorphic states, as part of a pilot study. The purpose of our investigation was to determine the appropriate level of data abstraction when reporting genetic test results in the EHR that would allow meaningful interpretation and clinical decision support based on current knowledge, while retaining sufficient information in order to enable reinterpretation of the results in the context of future discoveries. Methods: Based on the SNP & allele models, we designed two separate lab panels within the laboratory information system, one containing SNPs and the other containing alleles, built separate rules in the clinical decision support system based on each model, and evaluated the performance of these rules in an EHR simulation environment using real-world scenarios. Results: Although decision-support rules based on allele model required significantly less computational time than rules based on SNP model, no difference was observed on the total time taken to chart medication orders between rules based on these two models. Conclusions: Both, SNP- and allele-based models, can be used effectively for representing genetic test results in the EHR without impacting clinical decision support systems. While storing and reporting genetic test results as alleles allow for the construction of simpler decision-support rules, and make it easier to present these results to clinicians, SNP-based model can retain a greater amount of information that could be useful for future reinterpretation.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 50 条
  • [1] Frequencies of VKORC1-1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population
    Rathore, Saurabh S.
    Agarwal, Surendra K.
    Pande, Shantanu
    Mittal, Tulika
    Mittal, Balraj
    BIOSCIENCE TRENDS, 2010, 4 (06) : 333 - 337
  • [2] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [3] Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations
    Flores-Gutierrez, Sara
    Rodriguez-Larralde, Alvaro
    Vivenes de Lugo, Merlyn
    Castro de Guerra, Dinorah
    ANNALS OF HUMAN BIOLOGY, 2017, 44 (02) : 191 - 198
  • [4] Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
    Flockhart, David A.
    O'Kane, Dennis
    Williams, Marc S.
    Watson, Michael S.
    Flockhart, David A.
    Gage, Brian
    Gandolfi, Roy
    King, Richard
    Lyon, Elaine
    Nussbaum, Robert
    O'Kane, Dennis
    Schulman, Kevin
    Veenstra, David
    Williams, Marc S.
    Watson, Michael S.
    GENETICS IN MEDICINE, 2008, 10 (02) : 139 - 150
  • [5] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [6] Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin
    Pavani, Addepalli
    Naushad, Shaik Mohammad
    Stanley, Balraj Alex
    Kamakshi, Renganathan Gnanambal
    Abinaya, Krishnan
    Rao, Malempati Amaresh
    Uma, Addepally
    Kutala, Vijay Kumar
    PHARMACOGENOMICS, 2015, 16 (04) : 393 - 400
  • [7] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Lee, Hyun-Jee
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Yang, Ae-Yun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (07) : 1013 - 1019
  • [8] Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico
    Sanchez-Pozos, Katy
    Rivera-Santiago, Carolina
    Helena Garcia-Rodriguez, Maria
    Guadalupe Ortiz-Lopez, Maria
    Itzel Pena-Espinoza, Barbara
    de los Angeles Granados-Silvestre, Maria
    Llerena, Adrian
    Menjivar, Marta
    PHARMACOGENOMICS, 2016, 17 (17) : 1881 - 1889
  • [9] CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
    Scott, Stuart A.
    Jaremko, Malgorzata
    Lubitz, Steven A.
    Kornreich, Ruth
    Halperin, Jonathan L.
    Desnick, Robert J.
    PHARMACOGENOMICS, 2009, 10 (08) : 1243 - 1255
  • [10] PharmVar GeneFocus: CYP2C9
    Sangkuhl, Katrin
    Claudio-Campos, Karla
    Cavallari, Larisa H.
    Agundez, Jose A. G.
    Whirl-Carrillo, Michelle
    Duconge, Jorge
    Del Tredici, Andria L.
    Wadelius, Mia
    Botton, Mariana Rodrigues
    Woodahl, Erica L.
    Scott, Stuart A.
    Klein, Teri E.
    Pratt, Victoria M.
    Daly, Ann K.
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 662 - 676